Please select the eligibility criteria that correspond to the clinical trial below.
Title: ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia
Brief Summary: RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia.

PURPOSE: Thisphase III trial is studying several different combination chemotherapy regimens to compare how well they work in treating young patients with acute lymphoblastic leukemia.


Options:
A: DISEASE CHARACTERISTICS:

* Histologically confirmed acute lymphoblastic leukemia (ALL)
* No secondary ALL

PATIENT CHARACTERISTICS:

* No prior disease that would preclude treatment with chemotherapy

PRIOR CONCURRENT THERAPY:

* More than 4 weeks since prior chemotherapy
* More than 4 weeks since prior steroids
B: Inclusion Criteria:

* Previously untreated T-lineage or precursor B-lineage ALL
* Patients must have morphological proof of ALL and diagnosis must be made from bone marrow morphology with more than 25% blasts
* Written informed consent
* Treatment according to DCOG ALL 10 protocol

Exclusion Criteria:

* Mature B-lineage ALL
* Patients with secondary ALL
* Known allergy to any ASNase preparation
* General health status according to Karnofsky / Lansky score \< 40%
* Pre-existing known coagulopathy (e.g. haemophilia)
* Pre-existing pancreatitis
* Liver insufficiency (Bilirubin \> 50 µmol/L; SGOT/SGPT \> 10 x ULN)
* Other current malignancies
* Pregnancy (planned or existent), breast feeding
C: Inclusion Criteria:

* Histological diagnosis of nasopharyngeal carcinoma WHO type II or III

  * Stage I-IV disease
  * Newly diagnosed disease
* Performance status

  * Patients ≤ 16 years of age: Lansky 60-100%
  * Patients \> 16 years of age: Karnofsky 60-100%
* Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min
* Creatinine based on age/gender as follows:

  * No greater than 0.4 mg/dL (for patients 1 month to \< 6 months of age)
  * No greater than 0.5 mg/dL (for patients 6 months to \< 1 year of age)
  * No greater than 0.6 mg/dL (for patients 1-2 years of age)
  * No greater than 0.8 mg/dL (for patients \< 6 years of age)
  * No greater than 1.0mg/dL (for patients 6 to \< 10 years of age)
  * No greater than 1.2 mg/dL (for patients 10 to \< 13 years of age)
  * No greater than 1.4 mg/dL (for female patients 13 to ≥ 16 years of age)
  * No greater than 1.5 mg/dL (for male patients 13 to \< 16 years of age)
  * No greater than 1.7 mg/dL (for male patients ≥ 16 years of age)
* Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age
* AST or ALT \< 2.5 times ULN for age
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No prior chemotherapy or radiotherapy to the nasopharynx or neck for the treatment of nasopharyngeal carcinoma
D: Inclusion Criteria:

* Histologically confirmed acute lymphoblastic leukemia (ALL)
* No secondary ALL
* More than 4 weeks since prior chemotherapy
* More than 4 weeks since prior steroids

Exclusion Criteria:

* Prior disease that would preclude treatment with chemotherapy

Answer: A